Wendy Chung
CIK: 0001922605
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (13 total)
- Oct 26, 2026RLYB
Rallybio Corp
Exercise(M)Direct2.1K shares at avg. $15.28$32K - Sep 16, 2026RLYB
Rallybio Corp
Exercise(M)Direct3.6K shares at avg. $2.38$8K - Jun 5, 2026PRME
Prime Medicine, Inc.
Award(A)DirectStock Option (right to buy)
75K shares- - Aug 1, 2025PRME
Prime Medicine, Inc.
Disposition(D)DirectStock Option (right to buy)
13.5K shares- - Aug 1, 2025PRME
Prime Medicine, Inc.
Disposition(D)DirectStock Option (right to buy)
9K shares- - Aug 1, 2025PRME
Prime Medicine, Inc.
Award(A)DirectStock Option (right to buy)
9K shares- - Aug 1, 2025PRME
Prime Medicine, Inc.
Disposition(D)DirectStock Option (right to buy)
39.1K shares- - Aug 1, 2025PRME
Prime Medicine, Inc.
Award(A)DirectStock Option (right to buy)
39.1K shares- - Aug 1, 2025PRME
Prime Medicine, Inc.
Disposition(D)DirectStock Option (right to buy)
45K shares- - Aug 1, 2025PRME
Prime Medicine, Inc.
Award(A)DirectStock Option (right to buy)
45K shares- - Aug 1, 2025PRME
Prime Medicine, Inc.
Award(A)DirectStock Option (right to buy)
13.5K shares- - Jun 4, 2025PRME
Prime Medicine, Inc.
Award(A)DirectStock Option (right to buy)
55K shares- - May 13, 2025RLYB
Rallybio Corp
Award(A)DirectOption (Right to Buy)
28.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 26, 2026 |  RLYB Rallybio Corp | Exercise(M) | 2,062 | $15.28 | $31,507 | Direct |
| Sep 16, 2026 | RLYB Rallybio Corp | Exercise(M) | 3,562 | $2.38 | $8,478 | Direct |
| Jun 5, 2026 |  PRME Prime Medicine, Inc. | Award(A) Stock Option (right to buy) | 75,000 | - | - | Direct |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | Disposition(D) Stock Option (right to buy) | 13,510 | - | - | Direct |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | Disposition(D) Stock Option (right to buy) | 9,006 | - | - | Direct |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | Award(A) Stock Option (right to buy) | 9,006 | - | - | Direct |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | Disposition(D) Stock Option (right to buy) | 39,062 | - | - | Direct |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | Award(A) Stock Option (right to buy) | 39,062 | - | - | Direct |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | Disposition(D) Stock Option (right to buy) | 45,000 | - | - | Direct |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | Award(A) Stock Option (right to buy) | 45,000 | - | - | Direct |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | Award(A) Stock Option (right to buy) | 13,510 | - | - | Direct |
| Jun 4, 2025 | PRME Prime Medicine, Inc. | Award(A) Stock Option (right to buy) | 55,000 | - | - | Direct |
| May 13, 2025 | RLYB Rallybio Corp | Award(A) Option (Right to Buy) | 28,500 | - | - | Direct |
1-13 of 13 transactions
About Chung Wendy
Chung Wendy (SEC CIK 0001922605) files insider reports with the SEC as Director of Rallybio Corp (RLYB) and Director of Prime Medicine, Inc. (PRME).
Signal8 holds 6 ownership filings by Chung Wendy, all Form 4s, filed between May 15, 2025 and Oct 28, 2026. Those filings report 13 transactions, from May 13, 2025 to Oct 26, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Chung Wendy's filings is in EAST BERLIN, CT.
Recent filings by Chung Wendy
- Oct 26, 2026: Option exercise of RLYB shares (Form 4, code M).
- Sep 16, 2026: Option exercise of RLYB shares (Form 4, code M).
- Jun 5, 2026: Grant or award of PRME derivative securities (Form 4, code A).
- Aug 1, 2025: Disposition to issuer transactions of PRME derivative securities (2 lines, Form 4, code D).
- Aug 1, 2025: Grant or award of PRME derivative securities (Form 4, code A).
Other insiders filing for Rallybio Corp (RLYB)
- Lieber Jonathan I, Chief Financial Officer
- HUNT RONALD, Director
- Nash Christine A, Director
- Uden Stephen, Chief Executive Officer
- Soteropoulos Paula, Director
- Boudreau Helen M, Director